Mc002（adc）
Phase 1
Mc002（adc） is one of 18 therapeutic programs targeting Esophageal Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
20 competitors in Esophageal Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxol
TevaPhase 3
Adrucil
EElorac, Inc.
Approved
Taxotere
AAvyxa
Approved
Lenvima
EisaiPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Abraxane
Bristol-Myers SquibbPhase 2
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Mc002（adc）. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]